• Pila Pharma secured EMA clearance to run PP-CT04, a 12-week Phase II trial of XEN-D0501 in obesity.
• Study to assess safety, tolerability, pharmacokinetics, efficacy; dose titration from 4 mg twice daily up to 16 mg twice daily.
• Trial plans 46 participants across two parts, starting with an 8-person pilot safety cohort before expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.